Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.48 |
| ▸ | HTR3B | O95264 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR5A | P47898 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6626303 | 0.92 | POLB (0.44) | POLBSIGMAR1ADRB1HTR3EHTR3B | |
| SCHEMBL16107320 | 0.88 | POLB (0.42) | POLBSIGMAR1ADRB1HTR3EHTR3B | |
| SCHEMBL4055295 | 0.84 | ALDH1A1 (0.43) | KMT2AMEN1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL1829575 | 0.79 | KDM1A (0.46) | KMT2AMEN1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL1752645 | 0.79 | KDM1A (0.50) | POLBKMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL4147985 | 0.79 | ADRB1 (0.32) | POLBSIGMAR1ADRB1HTR3EHTR3B | |
| SCHEMBL861962 | 0.78 | PLK4 (0.39) | POLBSIGMAR1ADRB1HTR3EHTR3B | |
| SCHEMBL5551984 | 0.77 | ALDH1A1 (0.47) | HTR3AKMT2AMEN1ALDH1A1HTR6 | |
| SCHEMBL5550785 | 0.77 | HTR6 (0.53) | SIGMAR1ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL7141364 | 0.77 | CHRNB2 (0.47) | POLBKMT2AALDH1A1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122011344-A | Photo-thermal stable PTAA copolymer and preparation method thereof | 链行走新材料科技(广州)有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-11952363-B2 | Piperazine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2024-04-09 | — | — | US | claimed |
| CN-115304550-A | Piperazine phenyl amino substituted pyrimidine amino acid derivative, preparation method and application | 南通大学 | 2022-11-08 | — | — | CN | claimed |
| EP-3826724-B1 | NOVEL PIPERAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2022-10-05 | — | — | EP | claimed |
| US-20220031708-A1 | METHOD FOR TREATING IDIOPATHIC PULMONARY FIBROSIS | NUMEDII, INC. | 2022-02-03 | — | — | US | claimed |
| EP-3914284-A1 | METHOD FOR TREATING IDIOPATHIC PULMONARY FIBROSIS | Numedii, Inc. (US) | 2021-12-01 | — | — | EP | claimed |
| EP-3826724-A1 | NOVEL PIPERAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-06-02 | — | — | EP | claimed |
| CN-112584903-A | Novel piperazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2021-03-30 | — | — | CN | claimed |
| WO-2020154608-A1 | METHOD FOR TREATING IDIOPATHIC PULMONARY FIBROSIS | NUMEDII, INC. (US) | 2020-07-30 | — | — | WO | claimed |
| WO-2020020800-A1 | NOVEL PIPERAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-01-30 | — | — | WO | claimed |
| US-9353107-B2 | 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-05-31 | — | — | US | claimed |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2015-11-26 | — | — | US | claimed |
| CN-117886824-B | 2, 3-Dihydropyrimido [4,5-d ] pyrimidine-4 (1H) -ketone derivative, preparation method and application thereof | 四川大学华西医院 | 2026-05-15 | — | — | CN | disclosed |
| CN-122011344-A | Photo-thermal stable PTAA copolymer and preparation method thereof | 链行走新材料科技(广州)有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-108785265-B | Heterocyclic compounds and their use | 美国安进公司 | 2024-10-08 | — | — | CN | disclosed |
| CN-117946018-A | S-triazine LSD1 inhibitor and preparation method and application thereof | 郑州大学 | 2024-04-30 | — | — | CN | disclosed |
| US-6069143-A | Fibrinogen receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-30 | — | — | US | disclosed |
| EP-0885213-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0885213-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997025323-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952363-B2 | Piperazine compounds for the treatment of autoimmune disease | SSB, HLA-DRB1, IL5 | POLB 2189/4885SIGMAR1 2721/4885ADRB1 656/4885 |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | MAP3K3, MAP3K1, MAP3K6 | POLB 1830/4885SIGMAR1 2751/4885ADRB1 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.